HomeABUS • NASDAQ
add
Arbutus Biopharma Corp
Previous close
$2.75
Day range
$2.68 - $2.75
Year range
$1.69 - $3.29
Market cap
490.08M USD
Avg Volume
1.64M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 2.14M | -65.65% |
Operating expense | 5.10M | 20.05% |
Net income | -19.31M | 11.95% |
Net profit margin | -900.33 | -156.37% |
Earnings per share | -0.16 | 14.52% |
EBITDA | -20.16M | 2.35% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 126.00M | -14.23% |
Total assets | 144.40M | -26.11% |
Total liabilities | 38.38M | -34.46% |
Total equity | 106.02M | — |
Shares outstanding | 179.49M | — |
Price to book | 4.44 | — |
Return on assets | -33.86% | — |
Return on capital | -42.03% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -19.31M | 11.95% |
Cash from operations | -17.29M | -1.78% |
Cash from investing | 22.22M | 75.25% |
Cash from financing | 3.81M | -65.65% |
Net change in cash | 8.75M | 29.27% |
Free cash flow | -9.22M | -135.28% |
About
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Founded
2007
Headquarters
Website
Employees
73